New Triple-Target immune cell therapy enters first human trial for tough blood cancers

This is a first-in-human safety study testing a new, experimental CAR-T cell therapy called CAR19.20.22 in adults with B-cell lymphomas that have returned or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, engineered to attack cancer cells using three targets instead of one, which researchers hope will be more effective and prevent relapse. The main goals are to find a safe dose and see if the treatment shows early signs of working against these difficult cancers.